Speaker(s): 

Rachel Simon, MD, Staff Member, Geisinger - has nothing to disclose.
Mentor: Dr. Emily Sun

Moderator(s): 

Learning Objectives: 

1. 1. Discuss basic pathophysiology of TBI (primary injury, secondary injury)
   2. Explain the role of the selected biomarkers (S100B, GFAP, NSE, UCH-L1) in prognostication after moderate-to-severe TB
   3. Apply clinical judgment in understanding appropriate use of these biomarkers

At the conclusion of this session, the participant should be able to: 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Emily Sun, DO and Cortney Houtz, LPN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.

Questions: 

1. 1. After reading the article, do you feel that some (or all) of these biomarkers have clinical utility in neuroprognostication?
   2. How could this information affect your clinical judgement and decision making in a patient with a moderate to severe TBI?
   3. What is your outlook or opinion on our current methods for prognostication after severe neurological injury?